Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
4/23/24 | Neurocrine Biosciences (NBIX) | NBI-1065845 for Major Depressive Disorder (MDD) | Subscribers Only | Subscribers Only | Subscribers Only |
4/22/24 | Corcept Therapeutics (CORT) | Relacorilant for Cushing's Syndrome | Subscribers Only | Subscribers Only | Subscribers Only |
4/18/24 | AbbVie (ABBV) | Rinvoq for Giant Cell Arteritis | Subscribers Only | Subscribers Only | Subscribers Only |
4/17/24 | Eli Lilly (LLY) | Mounjaro for Sleep Apnea | Subscribers Only | Subscribers Only | Subscribers Only |
4/16/24 | Amgen (AMGN) | Tezspire for Chronic Obstructive Pulmonary Disease (COPD) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
03/01/24 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
03/19/24 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
04/09/24 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
04/15/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
04/15/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |